Recent research has shown that the three approved vaccines against the Corona virus in the United States are the most effective vaccines. However, experts point out some limitations in their analysis.
The US Centers for Disease Control and Prevention (CDC) published its findings based on a nationwide study of more than 3,600 adults who were hospitalized with COVID-19 between March and August. The results of the analysis showed that Moderna was 93 percent effective, while the Pfizer vaccine provided 88 percent. Protection from hospitalization, Johnson & Johnson 71 percent.
The study included adults who did not have immune disorders.
It was announced by a panel of experts in the CDC’s Weekly Report. The specialists concluded that while the data suggest some differences in the level of vaccine efficacy, all of those approved in America offer significant protection against hospitalization for COVID-19.
“The researchers found that the largest difference between Moderna’s vaccine and the Pfizer/Biontech vaccine was due to decreased immunity about four months after the second dose of Pfizer’s vaccine,” CNN reports.
As CNN adds, citing the team of researchers, the disproportion may also be due to the higher mRNA content in the Moderna vaccine, differences in time between doses (three weeks for Pfizer-BioNTech versus four weeks for Moderna) or possible differences between groups of people who received the vaccine. , which was not included in the analysis.
The team said that the effectiveness of the Pfizer-BioNTech vaccine was 91 percent after 14 to 120 days after receiving the second dose, but decreased significantly (to 77 percent) after more than 120 days.
CNN explains that vaccines from Pfizer and Moderna use a genetic material called messenger RNA to provide immunity. However, they use different dosages and slightly different formulas. The Janssen vaccine, which is owned by Johnson & Johnson, uses an inactivated cold virus called adenovirus to transmit genetic instructions into the body.
The researchers also admit that their analysis had some limitations.
“It did not include children or adults with immunodeficiency or the effectiveness of the COVID-19 vaccine in non-hospital conditions,” the team said. In addition, the volunteers were only followed for 29 weeks.
“Internet Geek. Food Enthusiast. Thinker. Beer Practitioner. Bacon Specialist. Music Addict. Traveler.”